Drug Trial Radar · NCT02522481
Evaluation of Safety and Efficacy of Lumason/SonoVue in Subjects Undergoing Pharmacologic Stress BR1-141
Last checked: Nov 20, 2026Latest source record: Jun 11, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
175
Actual
Start
Sep 24, 2015
Primary completion
Nov 7, 2017
Study completion Feb 25, 2018
Sponsor
- Lead sponsor
- Bracco Diagnostics, IncIndustry
- Sponsor type
- Industry
- First posted
- Aug 13, 2015
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Diagnostic
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study was to assess the safety and efficacy of Lumason-enhanced dobutamine stress echo (CE-DSE) in subjects having a suboptimal left ventricular endocardial border delineation (LV EBD) at rest and who were scheduled for coronary angiography.
Conditions
- Coronary Artery Disease
Interventions
LumasonDrug
Lumason (sulfur hexafluoride-type A microspheres) an ultrasound contrast agent was administered as 2 single 2-mL IV injections during rest and stress echocardiography
Primary outcomes
What the sponsor says the trial is designed to measure.
- Sensitivity and Specificity for Detection or Exclusion of Coronary Artery Disease (CAD)Time frame: Participants were followed until they had coronary angiography or up to 6 months post dose to collect clinical information on cardiac events if no coronary angiography were performed
- Reader-Specific Percentages of Participants Identified as Having a Critical Shift From Suboptimal to Optimal Echocardiographic ImagesTime frame: Participants were followed until they had coronary angiography or up to 6 months post dose to collect clinical information on cardiac events if no coronary angiography was performed
Locations
17 sites in 4 countries. Site status is shown where the registry gives one.
Sarver Heart Center, University of Arizona
Tucson, Arizona
University of California San Diego
La Jolla, California
Interventional Cardiology Medical Group, Inc.
West Hills, California
Cardiology Physicians, PA
Newark, Delaware
Community Heart and Vascular Community Hospital East
Indianapolis, Indiana
St. Luke's Mid-America Heart Institute
Kansas City, Missouri
North Kansas City Hospital
North Kansas City, Missouri
Morristown Medical Center
Morristown, New Jersey
The Institute for Clinical Research Holy Name Medical Center
Teaneck, New Jersey
Mount Sinai Medical Center
New York, New York
Mazankowski Alberta Heart Institute, University of Alberta Hospital
Edmonton, Alberta, Canada
Medizinische Klinik m.S. Kardiologie und Angiologie, Charité Universitätsmedizin Berlin
Berlin, Germany
Klinikum Lünen, St. Marien-Hospital GmbH
Lünen, Germany
Universitätsmedizin Mainz
Mainz, Germany
Kardiologie Klinik Dr. Müller GmbH, Peter Osypka Heart Center
Munich, Germany
Azienda Ospedaliera Universitaria Parma
Parma, Italy
Azienda Policlinico Umberto I Università degli Studi di Roma La Sapienza
Rome, Italy
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.